Coverage
-
August 08, 2011
A Texas federal judge ruled Friday that Par Pharmaceutical Cos. Inc. and two other drugmakers had infringed Pozen Inc.'s patents covering the migraine treatment Treximet and barred them from selling generic versions of the drug in the U.S. until certain patents expire.
1 other articles on this case.
View all »